FDA reviewing Amgen's migraine candidate

Amgen Inc. (NASDAQ:AMGN) said FDA accepted for review a BLA for Aimovig erenumab to prevent migraine in patients experiencing four or more migraine days per month. Its PDUFA date is May 17, 2018.

The BLA includes data from studies to treat both episodic and chronic migraine (see BioCentury Extra, Nov. 16, 2016)...